{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:16:17Z","timestamp":1779250577280,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Insmed Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12913-018-3489-8","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T10:12:40Z","timestamp":1536574360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8522-9354","authenticated-orcid":false,"given":"S. M.","family":"Goring","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. B.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. R.","family":"Risebrough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. J.","family":"Heap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Obradovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. R.","family":"Loebinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Diel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"issue":"3","key":"3489_CR1","first-page":"210","volume":"6","author":"MM Johnson","year":"2014","unstructured":"Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014;6(3):210\u201320.","journal-title":"J Thorac Dis"},{"issue":"2","key":"3489_CR2","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/QCO.0b013e3283511a64","volume":"25","author":"DE Griffith","year":"2012","unstructured":"Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis. 2012;25(2):218\u201327.","journal-title":"Curr Opin Infect Dis"},{"issue":"8","key":"3489_CR3","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1164\/rccm.201111-2016OC","volume":"185","author":"J Adjemian","year":"2012","unstructured":"Adjemian J, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med. 2012;185(8):881\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3489_CR4","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3201\/eid2206.151642","volume":"22","author":"FC Ringshausen","year":"2016","unstructured":"Ringshausen FC, et al. Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009-2014. Emerg Infect Dis. 2016;22(6):1102\u20135.","journal-title":"Emerg Infect Dis"},{"key":"3489_CR5","unstructured":"Wagner DvI, J, Adjemian J, Lange C, Prevots DR, Griffith D, Gallagher J, Gupta R, Haworth C. Annual prevalence and treatment estimates of nontuberculous mycobacterial pulmonary disease in Europe: A NTM-NET collaborative study. Eur Resp J. 2014;44(Suppl 58):P1067."},{"issue":"11","key":"3489_CR6","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3201\/eid1911.130737","volume":"19","author":"TK Marras","year":"2013","unstructured":"Marras TK, et al. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis. 2013;19(11):1889\u201391.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"3489_CR7","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1513\/AnnalsATS.201503-173OC","volume":"12","author":"SE Strollo","year":"2015","unstructured":"Strollo SE, et al. The burden of pulmonary nontuberculous mycobacterial disease in the United States. Ann Am Thorac Soc. 2015;12(10):1458\u201364.","journal-title":"Ann Am Thorac Soc"},{"issue":"6","key":"3489_CR8","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1183\/09031936.00149212","volume":"42","author":"W Hoefsloot","year":"2013","unstructured":"Hoefsloot W, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013;42(6):1604\u201313.","journal-title":"Eur Respir J"},{"issue":"5","key":"3489_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1164\/rccm.200905-0778OC","volume":"181","author":"C Andrejak","year":"2010","unstructured":"Andrejak C, et al. Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med. 2010;181(5):514\u201321.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3489_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","volume":"182","author":"DR Prevots","year":"2010","unstructured":"Prevots DR, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010;182(7):970\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3489_CR11","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1164\/rccm.201003-0503OC","volume":"182","author":"KL Winthrop","year":"2010","unstructured":"Winthrop KL, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010;182(7):977\u201382.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"3489_CR12","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.rmed.2011.08.004","volume":"105","author":"M Mehta","year":"2011","unstructured":"Mehta M, Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med. 2011;105(11):1718\u201325.","journal-title":"Respir Med"},{"issue":"8","key":"3489_CR13","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","volume":"174","author":"DE Griffith","year":"2006","unstructured":"Griffith DE, et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2006;174(8):928\u201334.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"3489_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1136\/thx.2007.087999","volume":"63","author":"PA Jenkins","year":"2008","unstructured":"Jenkins PA, et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax. 2008;63(7):627\u201334.","journal-title":"Thorax"},{"issue":"1","key":"3489_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.rmed.2014.10.013","volume":"109","author":"EP Gommans","year":"2015","unstructured":"Gommans EP, et al. Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study. Respir Med. 2015;109(1):137\u201345.","journal-title":"Respir Med"},{"issue":"4","key":"3489_CR16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"3489_CR17","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.rmed.2009.04.026","volume":"103","author":"GJ Ballarino","year":"2009","unstructured":"Ballarino GJ, et al. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med. 2009;103(10):1448\u201355.","journal-title":"Respir Med"},{"issue":"5","key":"3489_CR18","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1183\/09031936.00055010","volume":"37","author":"A Leber","year":"2011","unstructured":"Leber A, Marras TK. The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada. Eur Respir J. 2011;37(5):1158\u201365.","journal-title":"Eur Respir J"},{"issue":"11","key":"3489_CR19","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1017\/S0950268811002858","volume":"140","author":"SA Collier","year":"2012","unstructured":"Collier SA, et al. Direct healthcare costs of selected diseases primarily or partially transmitted by water. Epidemiol Infect. 2012;140(11):2003\u201313.","journal-title":"Epidemiol Infect"},{"key":"3489_CR20","doi-asserted-by":"publisher","unstructured":"Diel R, Jacob J, Lampenius N, Loebinger M, Nienhaus A, Rabe KF, Ringshausen FC. Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur Respir J. 2017;49(4):1602109. \n                    https:\/\/doi.org\/10.1183\/13993003.02109-2016\n                    \n                  .","DOI":"10.1183\/13993003.02109-2016"},{"key":"3489_CR21","volume-title":"Doctor Statistics in Canada, France, Germany, Italy, Japan, Spain, UK, USA 2008 Report","author":"EphMRA","year":"2008","unstructured":"EphMRA, Doctor Statistics in Canada, France, Germany, Italy, Japan, Spain, UK, USA 2008 Report. 2008."},{"key":"3489_CR22","unstructured":"OECD.Stat. PPPs and exchange rates. [cited 2016 Feb 12]; Available from: \n                    http:\/\/stats.oecd.org\/Index.aspx?datasetcode=SNA_TABLE4\n                    \n                  ."},{"key":"3489_CR23","volume-title":"R: A Language and Environment for Statistical Computing","author":"Team, R.C","year":"2016","unstructured":"Team, R.C. R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2016."},{"issue":"7","key":"3489_CR24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3201\/eid1907.120615","volume":"19","author":"P Seddon","year":"2013","unstructured":"Seddon P, et al. Prevalence of nontuberculous mycobacteria in cystic fibrosis clinics, United Kingdom, 2009. Emerg Infect Dis. 2013;19(7):1128\u201330.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"3489_CR25","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jiac.2014.05.010","volume":"20","author":"KW Jo","year":"2014","unstructured":"Jo KW, et al. Treatment outcomes of refractory MAC pulmonary disease treated with drugs with unclear efficacy. J Infect Chemother. 2014;20(10):602\u20136.","journal-title":"J Infect Chemother"},{"issue":"5","key":"3489_CR26","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1128\/AAC.02281-12","volume":"57","author":"WJ Koh","year":"2013","unstructured":"Koh WJ, et al. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen. Antimicrob Agents Chemother. 2013;57(5):2281\u20135.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3489-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-018-3489-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-018-3489-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T19:10:01Z","timestamp":1568056201000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-018-3489-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3489"],"URL":"https:\/\/doi.org\/10.1186\/s12913-018-3489-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"3 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Solutions institutional review board () reviewed the study (protocol # 2015\/11\/6) and verified it as exempt due to the lack of identifiers, use of existing data, and no direct contact with patients (45CFR46.101(b)(4): Existing Data & Specimens - No Identifiers).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SG, BW, NR, JRG, KH, and SC declare that they have no competing interests. RD has received a fee and\/or travel reimbursement for lectures or consultancy from Insmed. MO is an employee of Insmed, Incorporated. MRL has received consultancy and lecture fees from Insmed, not related to the production of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"700"}}